Whitehawk Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Whitehawk Therapeutics, Inc. The largest reported stake is Avoro Capital Advisors LLC's, at 19.99%. 5 filings are on record since August 25, 2025 (Schedule 13D/A, May 14, 2026).

ABG Management Ltd. also filed stake reports on 2 other companies ↓

Sell to companies like Whitehawk Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: ABG Management Ltd. · Sole voting: 0 · Shared voting: 817,939 · Sole dispositive: 0 · Shared dispositive: 817,939 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: OrbiMed Advisors LLC · Sole voting: 0 · Shared voting: 3,934,296 · Sole dispositive: 0 · Shared dispositive: 3,934,296 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-05-18 · Holder: Acuta Capital Partners, LLC · Percent: 9% · SCHEDULE 13D/A
• Filed 2026-05-14 · Holder: Avoro Capital Advisors LLC · Percent: 19.99% · SCHEDULE 13D/A
• Filed 2025-08-25 · Holder: Coastlands Capital LP · Percent: 5.98% · SCHEDULE 13G

Whitehawk Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-25. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Whitehawk Therapeutics, Inc. and the warning signs.

See Whitehawk Therapeutics, Inc.'s free Snapshot Watch Whitehawk Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Whitehawk Therapeutics, Inc. and the records around it.

Whitehawk Therapeutics, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Form D filing Mar 2025
• Who owns it

Companies that share a holder

• ABG Management Ltd. also filed stake reports on 2 other companies: ProMIS Neurosciences Inc. (Feb 2026), Ceribell, Inc. (Dec 2025)
• Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
• Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)

Want the whole picture on Whitehawk Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Whitehawk Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Whitehawk Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Whitehawk Therapeutics, Inc. by CUSIP 00032Q104 and gives its principal executive office as 2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960 (SCHEDULE 13G/A, 2026-08-14).

Purpose of Transaction (Item 4)

Avoro Capital Advisors LLC

On May 12, 2026, the Issuer entered into a Securities Purchase Agreement (the "2026 Securities Purchase Agreement") with Avoro Life Sciences Fund LLC ("Avoro Life") and certain other purchasers named therein (collectively, the "2026 PIPE Investors"). Pursuant to the 2026 Securities Purchase Agreement, the Issuer agreed to sell to Avoro Life an aggregate of 6,377,714 pre-funded warrants (the "Pre-Funded Warrants") to acquire Common Stock at a purchase price of $3.9199 per share (the "2026 PIPE Financing"). The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable, and remain exercisable until exercised in full. Avoro Life may not exercise a Pre-Funded Warrant if it, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. Avoro Life may decrease or, by providing at least 61 days' prior notice to the Issuer, increase such percentages not in excess of 19.99%. The foregoing summaries of the 2026 Securities Purchase Agreement and the Pre-Funded Warrants do not purport to be complete and are qualified in their entireties by reference to the 2026 Securities Purchase Agreement and the form of Pre-Funded Warrant, which are included as Exhibit 99.10 and Exhibit 99.11, respectively, hereto and are incorporated herein by reference. At the closing of the 2026 PIPE Financing, in connection with the 2026 Securities …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-14; the filing has the rest

Acuta Capital Partners, LLC

The reporting persons are filing this Schedule 13D because Mr. Dalal is on the Issuer's board of directors. The reporting persons acquired the Stock for investment purposes based on their belief that the Common Stock, when purchased, was undervalued and represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional Common Stock in the open market, through privately negotiated transactions with third parties or otherwise, and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the Common Stock that they now own or hereafter acquire. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-18; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Whitehawk Therapeutics, Inc.

Who owns Whitehawk Therapeutics, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Whitehawk Therapeutics, Inc.: Avoro Capital Advisors LLC (19.99%, Schedule 13D/A, filed 2026-05-14), Fan Yu (9.4%, Schedule 13G/A, filed 2026-08-14), Acuta Capital Partners, LLC (9%, Schedule 13D/A, filed 2026-05-18), OrbiMed Advisors LLC (7.3%, Schedule 13G/A, filed 2026-08-14) and Coastlands Capital LP (5.98%, Schedule 13G, filed 2025-08-25).

Who are the largest shareholders of Whitehawk Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Whitehawk Therapeutics, Inc. on this page are Avoro Capital Advisors LLC (19.99%), Fan Yu (9.4%) and Acuta Capital Partners, LLC (9%).

When did Avoro Capital Advisors LLC buy into Whitehawk Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Avoro Capital Advisors LLC on this page is the Schedule 13D/A, filed 2026-05-14, reporting 19.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Whitehawk Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Whitehawk Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Whitehawk Therapeutics, Inc. is mentioned again
• Find former Whitehawk Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes